Yupelri

Active Ingredient(s): Revefenacin
FDA Approved: * November 9, 2018
Pharm Company: * THERAVANCE BIOPHARMA
Category: Lungs (Pulmonary)

Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by chronic respiratory symptoms and airflow limitation. GOLD defines COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (shortness of breath, cough, sputum production or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction. The main symptoms of COPD inclu... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Yupelri 175 ug/3ml Respiratory (Inhalation) Solution
NDC: 49502-806
Labeler:
Mylan Specialty L.p.